GSK is a renowned brand in the pharmaceutical industry, dedicated to improving global health and healthcare access. With a strong focus on innovation, they offer a wide range of products and services to address various medical needs. In 2018, GSK made an agreement to acquire TESARO, an oncology-focused company, for approximately $5.

1 billion. This strategic move aims to strengthen GSK's pharmaceutical business by enhancing their pipeline and commercial capability in oncology. One of the key areas of innovation for GSK is the development of PARP inhibitors, which have shown transformative potential in the treatment of multiple cancer types.

These inhibitors have revolutionized the management of ovarian cancer, especially in patients with genetic mutations like BRCA. They have also demonstrated promising results in first line maintenance therapy, offering hope to a larger number of patients. Committed to advancing healthcare, GSK continues to prioritize research and development, leveraging the science of the immune system, human genetics, genomics, and advanced technologies.

They strive to tackle significant healthcare challenges worldwide and improve the lives of millions